Business
Change in the Board of Directors
Change in the Board of Directors.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\n \nFaron Pharmaceuticals Ltd. (\"Faron\" or the \"Company\")\nChange in the Board of Directors\nCompany announcement, September 8, 2023\nTURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that its non-executive Board member, Anne Whitaker, has notified the Company of her intention to step down from the Board of Directors from September 22, 2023, by the end of the Company's Extraordinary General Meeting (\"EGM\"), due to her new executive role at another company.\nSubject to the proposed election of Dr. Marie-Louise Fjällskog and Christine Roth to the Board of Directors at the forthcoming EGM and to regulatory approval, the Directors of the Company will be as follows:\n- Frank Armstrong (Chair)\n- Marie-Louise Fjällskog\n- Markku Jalkanen\n- Erik Ostrowski\n- John Poulos\n- Tuomo Pätsi\n- Christine Roth\n \nFor more information please contact:\nInvestor Contact\nLifeSci Advisors\nDaniel Ferry\nManaging Director\[email protected]\n+1 (617) 430-7576\n \nMedia Contact\nFaron Pharmaceuticals\nJennifer C. Smith-Parker\nHead of Communications\[email protected]\n \nCairn Financial Advisers LLP, Nomad\nSandy Jamieson, Jo Turner\nPhone: +44 (0) 207 213 0880\n \nPeel Hunt LLP, Broker\nChristopher Golden, James Steel\nPhone: +44 (0) 20 7418 8900\n \nSisu Partners Oy, Certified Adviser on Nasdaq First North\nJuha Karttunen\nPhone: +358 (0)40 555 4727\nJukka Järvelä\nPhone: +358 (0)50 553 8990\n \nAbout Bexmarilimab\nBexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages fr...